trelagliptin
Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus.
Ligand Summary
Target Activities
DPP4
Dipeptidyl peptidase 4
5 Activities
Items per page:
1 – 5 of 5
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | 8.89 | J Med Chem, (2017) 60:15:6480 | ||||
IC50 | 8.85 | Eur J Med Chem, (2017) 141:None:519 | ||||
IC50 | 8.4 | J. Med. Chem., (2011) 54:2:510 | ||||
Ki | 8.29 | Eur J Med Chem, (2017) 141:None:519 | ||||
IC50 | 8.4 | INHIBITOR | ||||